Showing 2,281 - 2,300 results of 14,387 for search '(( significant ((non decrease) OR (point decrease)) ) OR ( significant increase decrease ))', query time: 0.61s Refine Results
  1. 2281
  2. 2282
  3. 2283
  4. 2284
  5. 2285
  6. 2286
  7. 2287
  8. 2288

    CHAMPS pilot Hb dataset. by Jeanie du Toit (20721918)

    Published 2025
    “…Postmortem testing showed a significant decrease in hemoglobin concentrations compared to antemortem levels. …”
  9. 2289
  10. 2290

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  11. 2291

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  12. 2292

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  13. 2293
  14. 2294
  15. 2295
  16. 2296
  17. 2297
  18. 2298
  19. 2299
  20. 2300